Petosemtamab
Modify Date: 2024-04-08 20:47:13
Petosemtamab structure
|
Common Name | Petosemtamab | ||
|---|---|---|---|---|
| CAS Number | 2213450-26-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PetosemtamabPetosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC)[1][2]. |
| Name | Petosemtamab |
|---|
| Description | Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC)[1][2]. |
|---|---|
| Related Catalog | |
| Target |
EGFR:0.22 nM (Kd) LGR5:0.85 nM (Kd) |
| In Vitro | MCLA-158 (1 µg/mL, 24 or 72 h) leads to EGFR degradation in EGFR+/LGR5+ colorectal cancer organoids[2]. Western Blot Analysis[2] Cell Line: P18T (KRAS WT), C55T (KRAS G12V) and C82N (normal) organoids Concentration: 1 µg/mL Incubation Time: 1, 6, 24, 72 h Result: Time-dependently degraded EGFR. |
| In Vivo | MCLA-158 (25 mg/kg/week, i.v., for 6 weeks) leads to tumor regression in esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2]. Animal Model: Esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2] Dosage: 25 mg/kg/week Administration: Intravenous injection (i.v.) for 6 weeks. Result: Inhibited tumor growth. |
| References |
| No Any Chemical & Physical Properties |